Gilead Sciences Inc. [NASDAQ: GILD] traded at a high on 03/14/23, posting a 0.33 gain after which it closed the day’ session at $79.77. The company report on March 8, 2023 that Gilead Sciences: Global Community Accountability Groups Pave Way Forward for Inclusive Clinical Trials.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
(left to right) Bridget Ndagaano Jjuuko, Executive Director, ACTS 101 Uganda and Yvette Raphael, Executive Director, Advocacy for the Prevention of HIV/AIDS in South Africa.
The results of the trading session contributed to over 5497237 shares changing hands. Over the past one week, the price volatility of Gilead Sciences Inc. stands at 2.32% while the volatility over the past one month is 1.80%.
The market cap for GILD stock reached $98.79 billion, with 1.25 billion shares outstanding and 1.23 billion shares in the current float. Compared to the average trading volume of 6.59M shares, GILD reached a trading volume of 5497237 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Gilead Sciences Inc. [GILD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $89.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on January 03, 2023. While these analysts kept the previous recommendation, BofA Securities raised their target price to Neutral. The new note on the price target was released on December 13, 2022, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $90, while DZ Bank analysts kept a Hold rating on GILD stock. On October 31, 2022, analysts increased their price target for GILD shares from 60 to 76.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.60, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.62. The Price to Book ratio for the last quarter was 4.71, with the Price to Cash per share for the same quarter was set at 5.16. Price to Free Cash Flow for GILD in the course of the last twelve months was 21.31 with Quick ratio for the last quarter at 1.20.
How has GILD stock performed recently?
Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.64. With this latest performance, GILD shares dropped by -7.99% in over the last four-week period, additionally plugging by 17.29% over the last 6 months – not to mention a rise of 37.53% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 38.95, with the RSI for the last a single of trading hit 38.08, and the three-weeks RSI is set at 40.99 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 83.66, while it was recorded at 79.59 for the last single week of trading, and 73.02 for the last 200 days.
Gilead Sciences Inc. [GILD]: Deeper insight into the fundamentals
Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.30.
Earnings analysis for Gilead Sciences Inc. [GILD]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 2.52%.
Insider trade positions for Gilead Sciences Inc. [GILD]
There are presently around $82,458 million, or 83.00% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 131,560,250, which is approximately 2.413% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 112,038,324 shares of the stock with an approximate value of $8.94 billion in GILD stocks shares; and CAPITAL WORLD INVESTORS, currently with $5.5 billion in GILD stock with ownership of nearly 19.269% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 845 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 75,720,676 shares. Additionally, 855 investors decreased positions by around 49,190,496 shares, while 184 investors held positions by with 908,782,006 shares. The mentioned changes placed institutional holdings at 1,033,693,178 shares, according to the latest SEC report filing. GILD stock had 275 new institutional investments in for a total of 8,161,655 shares, while 106 institutional investors sold positions of 5,503,047 shares during the same period.